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 2 
Abstract 1 
Bone growth requires a specialised, highly angiogenic blood vessel subtype, so-called type H 2 
vessels1,2, which pave the way for osteoblasts surrounding these vessels3. At the end of 3 
adolescence, type H endothelial cells differentiate into quiescent type L endothelium lacking 4 
the capacity to promote bone growth. Until now, the signals that switch off type H vessel 5 
identity and thus arrest adolescent bone growth have remained ill defined. Here we show that 6 
mechanical forces, associated with increased body weight at the end of adolescence, trigger the 7 
mechanoreceptor PIEZO1 and thereby mediate enhanced production of the kinase FAM20C in 8 
osteoblasts. FAM20C phosphorylates dentin matrix protein 1 (DMP1)4, previously identified 9 
as a key factor in bone mineralization5. This phosphorylation elicits a burst in DMP1 secretion 10 
from osteoblasts. Extracellular DMP1 inhibits vascular endothelial growth factor (VEGF) 11 
signalling by preventing VEGFR2 phosphorylation and VEGFR3 expression on the tip cells of 12 
type H endothelium. DMP1-mediated VEGF inhibition transforms bone growth-promoting 13 
type H vessels into quiescent type L vasculature to arrest bone growth and enhance bone 14 
mineralization. This molecular mechanism links mechanical forces and the termination of bone 15 
growth via accumulation of an extracellular matrix protein and its regulation of vascular 16 
subtypes. It suggests new options for the treatment of diseases characterised by inappropriate 17 
turnover or invasion of bone such as osteoarthritis, osteoporosis and osteosarcoma. 18 
19 
 3 
DMP1 is a potential candidate controlling endothelial cell fate in bone 1 
To dissect age-related changes in vascular and perivascular microenvironments during and after active 2 
bone growth, we performed laser microdissection (LMD) of single capillary with associated 3 
surrounding cells in the ossification front (OF) of juvenile (4-week-old) and adult (12-week-old) mice. 4 
We developed a protocol to cut single capillary from undecalcified and unfixed bones of endothelial 5 
cell-specific GFP-reporter mice with a high RNA preservation rate to subsequently perform next-6 
generation sequencing (NGS) (Extended Data Fig. 1a,b). Principal component analysis showed that the 7 
cells from the juvenile OF were very similar between different mice, whereas with ageing, greater 8 
heterogeneity was apparent (Extended Data Fig. 1c). To identify candidates from the list of 9 
differentially expressed genes with a potential of regulating type H vasculature, we focused on 10 
extracellular matrix (ECM) proteins (Fig. 1a and Extended Data Fig. 1d). DMP1 appeared to be a 11 
promising candidate because of its ~4-fold higher expression in juvenile bones (Fig. 1a,b) and its 12 
reported anti-angiogenic activity in a retina tumour model6. 13 
DMP1 is known as an essential player in matrix mineralization5,7. Our detailed analysis of DMP1 14 
protein localization throughout postnatal bone development showed that until 5 weeks of age, the 15 
protein was mainly localized at the base of the zone of type H vessels in the OF (Fig. 1c,d). 16 
Unexpectedly, at the age of 5.5-6 weeks, a burst in DMP1 secretion into ECM occurred primarily in the 17 
central top part of the OF also reaching the growth plate (GP) (Fig. 1c,e-g and Extended Data Fig. 2a). 18 
We performed automated quantifications of protein staining intensities within central and peripheral 19 
regions of interest in the OF (Fig. 1f,g and Extended Data Fig. 2b). During late postnatal bone 20 
maturation with increasing age, the DMP1-occupied area spread from the centre towards the periphery 21 
of the OF. Finally, by the age of 12 weeks, the whole metaphysis together with the GP were interspersed 22 
with DMP1 (Fig. 1c,f,g). This behaviour was seen irrespective of sex. 23 
To identify the main cellular source of DMP1 in the OF-GP area at different ages, we established a 24 
method for RNAScope in bone. Co-hybridization was performed with probes for Dmp1 together with 25 
Runx2 for early osteoblasts, osterix (Osx or Sp7) for mature osteoblasts1 and sclerostin (Sost) for 26 
osteocytes8 (Extended Data Fig. 2c). Sclerostin expression was not found in the OF. At all analysed 27 
stages, Dmp1 mRNA was only detected in the OF area but never in the chondrocytes of the GP, 28 
 4 
including time points directly before (5 weeks) and during the burst in DMP1 protein secretion (5.5 1 
weeks) (Fig. 1h and Extended Data Fig. 2f). Dmp1 mRNA was mainly found in Osx+ cells and to a 2 
lesser extent in Runx2+ cells at all examined time points, which identifies osteoblasts as the main 3 
producer of DMP1 in the metaphysis (Extended Data Fig. 2d,e). The number and intensity of Dmp1-4 
expressing cells peaked at 4-5 weeks (Fig. 2i,j and Extended Data Fig. 2g). Yet, there was no difference 5 
at the level of Dmp1 gene expression between the central and peripheral parts of the OF, indicating that 6 
the observed differences in DMP1 amounts between these regions emerged rather at the protein level 7 
(cf. Fig. 1c,f,g). Together, these data demonstrate that the burst in DMP1 secretion from osteoblasts in 8 
the OF centre at the age of 5.5-6 weeks is controlled at the protein level and DMP1 likely diffuses from 9 
the OF to the GP (Fig. 1k). 10 
 11 
DMP1 transforms type H vessels into type L 12 
In addition to secreting osteogenic factors2, tip cells of type H vessels secrete matrix metalloproteinase 13 
9 (MMP9) that digests cartilage matrix and allows vessel bulges to invade GP cartilage, thereby 14 
facilitating bone growth9. We noticed that DMP1 accumulation in the OF centre at 5.5-6 weeks 15 
correlated with a decrease in endomucin (EMCN) intensity and reduced amounts of MMP9 at the OF-16 
GP border. This was associated with the disappearance of bulges and columnar structure of the vessels 17 
(Fig. 2a,b, Extended Data Fig. 3). Hence, all main features of type H vessels were downregulated. 18 
Importantly, at 5.5-6 weeks, these changes occurred only in the central part of the OF. 19 
To study whether DMP1 directly regulated bone angiogenesis and growth, we generated mice with a 20 
constitutive and an inducible deletion of Dmp1 (Extended Data Fig. 4). Constitutive Dmp1-deficient 21 
mice were smaller with shortened and widened long bones (Extended Data Fig. 4c-f) as had been 22 
described before5,10, and they featured a disorganized OF and GP (Extended Data Fig. 5a). The blood 23 
vessels in the OF were dilated and had very high EMCN and MMP9 intensity, even in adulthood, though 24 
the columnar structure was lost already in juvenile bones (Extended Data Fig. 5c,d). This finding 25 
suggests that, presumably via its matrix mineralization activity, DMP1 provides a scaffold for columns 26 
of type H vessels. The phenotype of Dmp1+/- mice was identical to Dmp1+/+ mice, which indicates that 27 
one Dmp1 allele generates sufficient DMP1 protein (Extended Data Fig. 4c,d and 5b). This result is 28 
 5 
consistent with human genetic studies where it was shown that mutations in the Dmp1 gene cause 1 
autosomal recessive hypophosphatemia11. OSX+ and RUNX2+ osteoblasts were present in the OF to a 2 
similar extent as in the wild-type group indicating that DMP1 is not required for osteoblast 3 
differentiation and maturation12 (Extended Data Fig. 5a,b). Notably, the GP of Dmp1-/- mice exhibited 4 
an expanded pre-hypertrophic and hypertrophic zone (RUNX2+ and SOX9+) (Extended Data Fig. 5a). 5 
We assume that this phenotype is caused by the lack of proper vessel invasion due to the loss of vessel 6 
architecture.  7 
To test whether DMP1 induces the switch from type H to type L vessels, we generated a Dmp1-floxed 8 
mouse line and crossed it with Col1-CreERT2 mice to ablate Dmp1 in an inducible manner selectively 9 
in osteoblasts (Dmp1i∆OB) upon tamoxifen injection (Extended Data Fig. 4g-i). Deletion of Dmp1 was 10 
performed at P28-32 to allow normal formation of the OF together with the columnar structure of blood 11 
vessels (Fig. 2c). Tamoxifen treatment led to ~75% reduction of Dmp1 mRNA expression by week 6 12 
(P42) (Extended Data Fig. 6a,b) and reduced the amount of DMP1 protein in the OF centre by ~70% 13 
(Fig. 2d and Extended Data Fig. 6c). The body weight was not affected (Extended Data Fig. 6d). Yet, 14 
long bones of Dmp1i∆OB mice featured an enlarged metaphysis with overall increased EMCN and 15 
MMP9 intensities (Fig. 2e,f and Extended Data Fig. 6e). In line with the femur phenotype of constitutive 16 
Dmp1-deficient mice (cf. Extended Data Fig. 4d,f), also Dmp1i∆OB femurs were slightly shorter than 17 
control femurs by the age of 6 weeks, presumably reflecting the key role of DMP1 in matrix 18 
mineralization and bone architecture (Extended Data Fig. 6f). Nevertheless, detailed analysis showed 19 
that the deletion of Dmp1 in osteoblasts arrested the age-related maturation of the OF. Specifically, type 20 
H vessels together with bulges were preserved in the central part of the OF in Dmp1i∆OB mice (Fig. 21 
2g,h). Moreover, the difference in EMCN and MMP9 intensity between the central and peripheral parts 22 
of the OF was absent in Dmp1i∆OB femurs (Fig. 2i,k). The overall EMCN intensity and MMP9 amount 23 
in the OF centre were higher in Dmp1i∆OB samples compared with the control group (Fig. 2j,l). As 24 
expected, von Kossa staining showed reduced mineralization of the OF in Dmp1i∆OB femurs, confirming 25 
the crucial importance of DMP1 for bone calcification (Extended Data Fig. 6g,h,j). 26 
In line with the phenotype of Dmp1i∆OB mice at the OF, analysis of subchondral bone revealed that 27 
Dmp1 deletion at 4 weeks led to preserved density of EMCN+ vessels and high amounts of MMP9 28 
 6 
around the vessel tips underneath the articular cartilage by week 6 (Fig. 2m-o). Control mice featured 1 
significantly reduced vessel activity in subchondral bone, whereas Dmp1i∆OB samples were very similar 2 
to 4-week-old wild-type subchondral bone. Thus, deletion of Dmp1 at 4 weeks prevented the 3 
development-associated switch from active to quiescent vessel fate not only at the OF but also in 4 
subchondral bone. The mineralization of subchondral bone was also reduced in Dmp1i∆OB femurs 5 
(Extended Data Fig. 6g,i,k). In summary, these results demonstrate that, apart from its canonical 6 
function in matrix mineralization, DMP1 induces the transformation of active type H into quiescent 7 
type L vessels, which results in reduced EMCN and MMP9 expression and loss of vessel bulges. 8 
 9 
DMP1 inhibits VEGF signalling in the ossification front 10 
To test whether DMP1 has VEGF-inhibiting properties in bone, we studied phosphorylation of the main 11 
VEGF receptor VEGFR2 (pVEGFR2) along with DMP1 accumulation in ECM. Local DMP1 amounts 12 
negatively correlated with the amount of phosphorylated VEGFR2 (Fig. 3a and Extended Data Fig. 7a). 13 
The VEGFR2 phosphorylation level in 4- to 5-week-old mice was equal across the OF. However, at 14 
5.5-6 weeks we observed a marked reduction in the amount of pVEGFR2 in the central part of the OF 15 
in wild-type mice. This difference was largely lost in Dmp1i∆OB mice, and the overall intensity of 16 
pVEGFR2 in the OF centre was higher (Fig. 3b-d). Of note, the total level of VEGFR2 protein was not 17 
affected by Dmp1 deletion (Fig. 3e,g). 18 
Previous studies showed that VEGFR2 activation induces VEGFR3 expression in endothelial cells13,14. 19 
VEGFR3 is usually highly upregulated in endothelial tip cells, where it plays a crucial role in vessel 20 
sprouting13,15,16. Bulges in the GP of Dmp1i∆OB mice stained strongly with VEGFR3 compared with 21 
remaining bulges of control mice (Fig. 3f,h). This result suggests that osteoblast-released DMP1 22 
downregulates VEGFR3 in endothelial tip cells most likely by interference with VEGFR2 signalling, 23 
thus leading to the loss of vessel bulges. Further support came from the finding that treatment of the 24 
capillary endothelial cell line bEnd.3 with DMP1 abrogated the VEGF-induced phosphorylation of 25 
VEGFR2 and the expression of cfos, a target gene of VEGF signalling17 (Extended Data Fig. 7b-d). 26 
Taken together, these data demonstrate that in the OF, DMP1 inhibits VEGF signalling, which is a 27 
known driver of angiogenesis and osteogenesis18–20. 28 
 7 
Mechanical forces trigger PIEZO1 to enhance FAM20C kinase production and DMP1 secretion 1 
Hormones, especially sex hormones, are usually considered important regulators of bone growth and 2 
metabolism21–23. Mice achieve puberty by approximately week 6, which coincides in time with the burst 3 
in DMP1 secretion. We noticed that the extent of DMP1 release at 5.5-6 weeks varied considerably 4 
between individual mice (cf. Fig. 1f). We also noted that in mice with lower body weight than average, 5 
the burst in DMP1 secretion had not yet taken place at 5.5-6 weeks. Inversely, littermates heavier than 6 
average featured already very advanced DMP1 release at this time point (Fig. 3i). Indeed, we found a 7 
positive correlation between body weight and the extent of DMP1 secretion (Fig. 3j). Since DMP1 is 8 
also a key factor in matrix mineralization, we hypothesised that mechanical force, directly or indirectly, 9 
controls DMP1 secretion.  10 
FAM20C is the kinase mediating the phosphorylation and subsequent secretion of DMP1 into ECM4. 11 
Notably, in 6-week-old mice, we found more FAM20C, along with higher DMP1 accumulation, in the 12 
OF centre in comparison to the periphery, which was not the case in 4-week-old mice (Fig. 3k-m). In 13 
line with FAM20C acting upstream of DMP1, inducible Dmp1 deletion did not impair FAM20C 14 
upregulation at the age of 6 weeks (Extended Data Fig. 8a,b). 15 
To investigate whether FAM20C production was enhanced by mechanical loading, we cultured live 16 
400-500-µm-thick slices of 4-week-old femurs and centrifuged them twice daily on 5 consecutive days 17 
(Fig. 4a). Loading via centrifugation caused an upregulation of intracellular FAM20C protein and 18 
enhanced DMP1 secretion (Fig. 4b,c and Extended Data Fig. 8c,d). The mechanically induced FAM20C 19 
upregulation apparently occurred hormone-independently in the cultured femur slices in vitro. 20 
To study if body weight-associated mechanical forces control FAM20C production also in vivo, we 21 
unloaded one hind limb in the mouse by cutting the sciatic and femoral nerves at the age of 4.5 weeks 22 
(Fig. 4d). This results in paralysis of the affected hind limb with all weight going through the 23 
contralateral (normal) side, whereas both limbs were exposed to the same hormonal environment. 24 
Unloading by double neurectomy prevented FAM20C upregulation and DMP1 secretion at 5.5-6 weeks 25 
in almost all of the operated limbs, whilst preserving normal release on the contralateral side (Fig. 4e,f 26 
and Extended Data Fig. 8e,f).  27 
 8 
In our transcriptome analysis, we found 4 mechanoreceptors that osteoblasts could potentially express 1 
in the OF during late postnatal development: Trpv4, Kcnk2, Piezo1, Piezo2 (Extended Data Fig. 8g). 2 
Recently published studies show that in osteoblasts, mainly PIEZO1 and to a lesser extent PIEZO2 are 3 
key mechanosensors mediating anabolic effects of loading on bone24–28. Thus, we tested whether 4 
PIEZO1 or PIEZO2 control Fam20c upregulation in osteoblasts by analysis of bones of 6-7-week-old 5 
mice with Piezo1 or Piezo2 deficiency in Dmp1-expressing cells (Piezo1∆Dmp1 or Piezo2∆Dmp1). FAM20C 6 
upregulation and the resulting burst in DMP1 secretion were lost exclusively in Piezo1∆Dmp1 bones but 7 
normal in Piezo2∆Dmp1 femurs (Fig. 4g-m and Extended Data Fig. 8h). Importantly, osteoblast 8 
maturation and abundance were not affected by Piezo1 deletion both at 4 and 7 weeks (Extended Data 9 
Fig. 8i-k). 4-week-old Piezo1∆Dmp1 bones featured similar levels of FAM20C and DMP1 as control 10 
bones indicating that PIEZO1 mediates the weight-induced upregulation of FAM20C around 11 
periadolescence, whereas basal FAM20C expression is PIEZO1 independent (Extended Data Fig. 8l-12 
n). To conclude, mechanical forces trigger PIEZO1 to enhance FAM20C expression and subsequent 13 
DMP1 secretion in osteoblasts. 14 
Discussion 15 
In this study, we identify a two-step molecular mechanism by which mechanical forces limit growth of 16 
long bones and drive bone maturation at the end of adolescence (Extended Data Fig. 9). First, body 17 
weight-associated mechanical loading triggers the mechanoreceptor PIEZO1 to enhance the production 18 
of FAM20C kinase in osteoblasts, which induces a burst in DMP1 secretion into extracellular matrix. 19 
Second, large amounts of extracellular DMP1 inhibit VEGF signalling in the OF and transform highly-20 
angiogenic type H vessels into quiescent type L vasculature to arrest bone growth. In parallel, 21 
extracellular DMP1 leads to rapid matrix mineralization and strengthening of long bones5,29,30. Thus, 22 
the role of DMP1 in bone is multifaceted: it combines active inhibition of angiogenesis with 23 
mineralizing activity. The discovered link between mechanical loading and FAM20C upregulation, a 24 
major kinase of the bone phosphoproteome, provides a mechanistic explanation for the well-known 25 
positive effect of loading on bone mineralization31. Furthermore, it may offer a mechanistic explanation 26 
for hormone-independent osteoporosis caused by lack of loading, for example in astronauts32,33 or after 27 
long immobilization of a fractured bone34.  28 
 9 
Growth-promoting type H vessels have received much attention in the last years because of their 1 
substantial clinical potential35,36. Our finding that inducible Dmp1 deletion led to increased vessel 2 
activity also in subchondral bone suggests that extracellular DMP1 may protect articular cartilage from 3 
vessel invasion, which accompanies neoinnervation of the tissue and sensation of pain in osteoarthritis 4 
patients37-38. Moreover, DMP1-mediated inhibition of angiogenesis in bone may be useful in arresting 5 
growth of tumours including osteo- and chondrosarcomas39-41. 6 
Under the influence of systemic hormones, bones of male mice acquire higher mass and cortical 7 
thickness than females, which is already evident at early puberty42 (3-5 weeks). As the weight of male 8 
mice is also greater than females at this stage it is likely that the load perceived by individual osteoblasts 9 
in male and female bones is equivalent during growth according to the principles of isometric scaling43. 10 
This may explain why the triggering of FAM20C upregulation and DMP1 secretion happens in both 11 
genders at the same age despite the difference in absolute body weight, and presumably after a key 12 
mechanical threshold has been reached. Our results suggest that mechanical force is a key player in the 13 
control of bone growth termination, acting on bones in addition to systemic sex hormones21-23. 14 
Growth plate injuries are one of the most common types of fractures in children44 since the OF-GP 15 
border is the weakest and most flexible part of the bone. From an evolutionary perspective, it appears 16 
desirable to have loading-dependent mechanisms as a protective feedback in place that with increasing 17 
body weight, drive bone maturation and improve durability via enhanced calcification and simultaneous 18 
growth inhibition. 19 
Based on our finding that FAM20C upregulation is induced by loading and it happens first in the OF 20 
centre, we hypothesize that the central part of the OF is exposed to the highest mechanical strain since 21 
it is a spot where the loading from all four domes of the GP gets integrated. Moreover, there is no 22 
cortical bone underneath to absorb this loading (Extended Data Fig. 8o).  23 
The findings presented here demonstrate that mechanical forces transmitted through PIEZO1 play a 24 
crucial role in the regulation of skeletal development and bone maturation via FAM20C-mediated 25 
extracellular DMP1 accumulation and its control of blood vessel subtypes in bone. This knowledge may 26 
be applied in bone healing studies45, as well as in different kinds of bone pathologies featuring abnormal 27 
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Fig. 1: Burst in DMP1 secretion from osteoblasts into ECM at the OF-GP border during periadolescence.  1 
a, Volcano plot of significantly differentially expressed genes in juvenile (4 weeks, n=5) versus adult (12 weeks, 2 
n=4) capillary with surrounding cells from the ossification front (OF) (mean expression value >500, red: Log2 FC > 3 
0.66, P < 10-5). b, Log2 transformed number of reads mapped to the Dmp1 gene. c, DMP1 immunostaining in the 4 
OF throughout postnatal bone development. Red arrows point at DMP1 at the OF base. Scale bar 250 µm. d, 5 
DMP1 and endomucin (EMCN) immunostaining of the OF from 5-week-old femur. Red arrows point at type H 6 
vessels. Scale bar 50 µm. e, Schematic depiction of the femur with a green plane going through the centre of the 7 
bone, where DMP1 secretion is observed. Example of DMP1 immunostaining of a section taken from the middle 8 
part of the femur, showing the definition of the central and peripheral regions used for further automated 9 
quantification. Scale bar 250 µm. f, Quantification of DMP1 staining intensity in the centre and periphery of the OF 10 
throughout bone development. Mean ± SD. g, Quantification of the contribution of the central and peripheral part 11 
to the total DMP1 amount. Mean ± SD. f,g, at 4 weeks n=7, 5 weeks n=5, 5.5-6 weeks n=10, 8 weeks n=5, 12-15 12 
weeks n=6. Pooled data from 5 independent experiments. P values show the significance between the intensity in 13 
the centre versus periphery for every mouse (paired analysis). Two-tailed Wilcoxon matched-pairs signed rank 14 
test. h, Dmp1 mRNA (RNAScope) of the central regions of OF and GP from 5- and 5.5-week-old femurs. Lack of 15 
Dmp1 expression in chondrocytes of the GP; yellow frame indicates the region shown in Fig. 1i. Scale bar 50 µm. 16 
i, RNAScope images of Dmp1, Osterix (Osx) and Runx2 (only depicted in Extended Data Fig. 2c). Scale bar 50 17 
µm. j, Number of Dmp1-expressing cells in the central and peripheral region of the OF based on RNAScope 18 
images. n=3 per age. Pooled data from 2 independent experiments. Mean ± SD. k, DMP1 and EMCN 19 
immunostaining of 5.5-week-old femur. Infiltration of DMP1 from the OF into the GP. Scale bar 50 µm. 20 
  21 
 14 
Fig. 2: DMP1 transforms active type H vessels into quiescent type L in the ossification front and in subchondral bone. 1 
a, EMCN and MMP9 immunostaining of femur throughout postnatal development. Dashed line shows the OF-GP border. White 2 
arrows point at type H vessels. Scale bar 50 µm. b, Quantification of the contribution of the central and peripheral parts to the 3 
total EMCN intensity. At 4 and 5 weeks n=7, 5.5-6 weeks n=12, 8 weeks n=6, 12-15 weeks n=6. Pooled data from 6 independent 4 
experiments. P value shows the significance between the intensity in the centre versus periphery for every mouse (two-tailed 5 
paired t-test, significant only for 5.5-6 weeks). Mean ± SD. c, Experimental scheme to induce Dmp1 deletion by Tamoxifen 6 
injection starting at 4 weeks (P28-32) and to analyse bones at 6 weeks (P42). d, Quantification of DMP1 protein amount in the 7 
OF centre of control and osteoblast-specific inducible Dmp1-deleted (Dmp1i∆OB) mice. Two-tailed Mann Whitney test. e, EMCN 8 
and MMP9 immunostaining of 6-week-old control and Dmp1i∆OB femurs. Scale bar 500 µm. f, Quantification of ossification front 9 
length to femur length ratio in control and Dmp1i∆OB mice. d,f, Control n=14, Dmp1i∆OB n=13. g, Quantification of bulges by 10 
measuring the total EMCN intensity in the central bottom part of the GP (500µm long) in control and Dmp1i∆OB mice. Two-tailed 11 
Mann Whitney test. h, EMCN and MMP9 immunostaining of femur in 6-week-old control and Dmp1i∆OB mice. Dashed line shows 12 
the OF-GP border. Scale bar 50 µm. i, Quantification of the central to peripheral intensity ratio of EMCN in control and Dmp1i∆OB 13 
OF. Two-tailed paired t-test. j, Quantification of the total central EMCN intensity in control and Dmp1i∆OB group. Two-tailed 14 
unpaired t-test. k, Quantification of MMP9 in the centre relative to the periphery at the OF-GP border in control and Dmp1i∆OB 15 
femurs. Two-tailed paired t-test. l, Quantification of the total central MMP9 amount at the OF-GP border in control and Dmp1i∆OB 16 
group. Two-tailed Mann Whitney test. g-l, Pooled data from 3 independent experiments. Control n=11, Dmp1i∆OB n=13. Age: 6 17 
weeks. Mean ± SD. m, EMCN and MMP9 immunostaining of 6-week-old control, Dmp1i∆OB and 4-week-old wild-type (WT) 18 
subchondral bone (SB) with articular cartilage (AC). Dashed line indicates the SB-AC border. Scale bar 50 µm. n, Quantification 19 
of the total EMCN intensity at the SB-AC border (500 µm long). o, Quantification of the total MMP9 intensity around the vessels 20 
at the SB-AC border (500 µm long). m-o, Pooled data from 2 independent experiments. Control n=11, Dmp1i∆OB n=9, 4-week-old 21 
WT n=4. Mean ± SD. 22 
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 1 
Fig. 3: Extracellular DMP1 inhibits VEGF signalling in the OF and coincides spatiotemporally with FAM20C 2 
upregulation. a, Quantification of the centre to periphery ratio of phosphorylated VEGFR2 (pVEGFR2) and DMP1 3 
amount at different ages. At 4 and 5 weeks n=7, 5.5-6 weeks n=6, 8 weeks n=5, 12-15 weeks n=4. Pooled data 4 
from 3 independent experiments. Mean ± SD. b, Quantification of pVEGFR2 amount in the centre relative to 5 
periphery in control and Dmp1i∆OB OF. Two-tailed Wilcoxon matched-pairs signed rank test. c, Quantification of the 6 
total central pVEGFR2 amount in control and Dmp1i∆OB group. Two-tailed unpaired t-test. b,c, Pooled data from 3 7 
independent experiments. Control n=9, Dmp1i∆OB n=11. Age: 6 weeks. Mean ± SD. d, pVEGFR2 immunostaining 8 
showing no decrease of pVEGFR2 in the OF centre of Dmp1i∆OB femurs in contrast to control femurs at 6 weeks 9 
of age. Scale bar 25 µm. e,f, VEGFR2 and EMCN (e) and VEGFR3 and EMCN (f) immunostaining of the OF centre 10 
in 6-week-old control and Dmp1i∆OB mice. Scale bar 50 µm. g, Quantification of VEGFR2 intensity in EMCN+ 11 
endothelial cells in the OF of control and Dmp1i∆OB mice. Control n=4, Dmp1i∆OB n=4. Pooled data from 2 12 
independent experiments. Two-tailed Mann Whitney test. Median ± range. h, Quantification of VEGFR3 intensity 13 
in the OF of control and Dmp1i∆OB mice. Control n=6, Dmp1i∆OB n=9. Pooled data from 3 independent experiments. 14 
Two-tailed Mann Whitney test. Median ± range. i, DMP1 and EMCN immunostaining of 5.5-week-old femurs 15 
derived from littermate mice. Red dotted line marks the area of extracellular DMP1 at the OF. Scale bar 250 µm. j, 16 
Counterplot of body weight versus DMP1 intensity. R2 = 0.4139, n=19. k, Quantification of FAM20C intensity in the 17 
centre relative to periphery (centre + periphery) in 4- and 6-week-old femurs. Two-tailed paired t-test. l, 18 
Quantification of FAM20C intensity in the centre in 4- and 6-week-old femurs. Two-tailed paired t-test. k,l, Pooled 19 
data from 2 independent experiments. At 4 weeks n=6, 6 weeks n=5. m, FAM20C and DMP1 immunostaining in 20 





Fig. 4: Mechanical forces trigger PIEZO1 to enhance FAM20C kinase production and DMP1 secretion. 3 
a, Schematic depiction of the position of a femur slice (≈500 µm thick) derived from 4-week-old mice in a well of a 4 
96-well PCR plate filled with cell culture medium. The slices were either just cultured for 5 days (control) or exposed 5 
to loading via low-speed centrifugation (30 min. at 19g) twice per day (loaded). b, Quantification of FAM20C and 6 
DMP1 intensities in the loaded (centrifuged) samples relative to control (non-centrifuged) group (red line). Pooled 7 
data from 2 independent experiments. Mean, n=5-6. P values for paired analysis of samples derived from one 8 
mouse. Two-tailed paired t-test. c, FAM20C and DMP1 immunostaining of control and loaded (centrifuged) femur 9 
slices. Scale bar 100 µm. d, Experimental setup for hind limb unloading via sciatic and femoral double neurectomy 10 
at the age of 4.5 weeks. e, Quantification of FAM20C and DMP1 intensities in the unloaded femur relative to the 11 
loaded control (red line) at 5.5 weeeks. P values show significance after paired analysis of intensities derived from 12 
the same mouse. Pooled data from 2 independent experiments. Two-tailed Wilcoxon matched-pairs signed rank 13 
test. Median, n=16. f, FAM20C and DMP1 immunostaining of loaded (control, left hind limb) and unloaded 14 
(operated, right hind limb) femurs at 5.5 weeeks. Scale bar 50 µm. g, Quantification of Fam20c mRNA based on 15 
RNAScope images of 7-week-old control and Piezo1∆Dmp1 OF. n=5. Two-tailed unpaired t-test. h, FAM20C and 16 
DMP1 immunostaining of 7-week-old control and Piezo1∆Dmp1 OF. Scale bar 50 µm. i,j, Quantification of FAM20C 17 
(i) and DMP1 (j) intensities in 7-week-old control and Piezo1∆Dmp1 OF. n=5. Two-tailed unpaired t-test. k, FAM20C 18 
and DMP1 immunostaining of 6-week-old control and Piezo2∆Dmp1 OF. Scale bar 50 µm. l,m, Quantification of 19 
FAM20C (l) and DMP1 (m) intensities in 6-week-old control and Piezo2∆Dmp1 OF. n=4. Two-tailed unpaired t-test. 20 
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Extended Data 1 
Extended Data Fig. 1: Laser microdissection and sequencing of endothelial cells with surrounding cells 2 
from ossification front of juvenile and adult femurs. a, Image of the metaphysis in a section from a snap-frozen 3 
femur directly before laser microdissection (LMD) (top). Epifluorescent image of Tie2-GFP+ endothelial cells in the 4 
OF of the snap-frozen femur (middle). GFP+ regions were cut out and collected. Image of the metaphysis directly 5 
after LMD with visible holes after cutting out the capillary with surrounding cells, which were collected for further 6 
transcriptome analysis via next-generation sequencing (NGS) (bottom). b, Bioanalyzer plot showing good RNA 7 
integrity number (RIN) of RNA isolated from laser-microdissected sample from femur section processed according 8 
to the protocol we developed. The sample consisted of larger laser-microdissected pieces from OF, since the 9 
amount of RNA in the real sample (single capillary with surrounding cells) was below the detection limit of 10 
Bioanalyzer. c, Principal component analysis of the juvenile (4-week-old) and adult (12-week-old) capillary with 11 
surrounding cells from OF, which we obtained via LMD, showing that most of the difference is derived from the 12 
different sample groups and the heterogeneity within the group increases with ageing. d, Heat map of the most 13 
highly and significantly differentially regulated genes in the juvenile versus adult group, where dentin matrix protein 14 
1 (Dmp1) was identified as an interesting candidate for further analysis. Genes encoding ECM proteins are set in 15 
italics. Mean expression value >500, Log2 FC > 0.66, P < 10-5.  16 
17 
 18 
Extended Data Fig. 2: Osteoblasts are the main DMP1 producer in the metaphysis and automated 1 
quantification strategy of histological images. a, DMP1 immunostaining of sections taken from the middle (left 2 
image, green plane in the scheme) or distal (right image, red plane in the scheme) part of the femur. Yellow dashed 3 
rectangles indicate the analysis areas that were defined as centre and periphery and used for further automated 4 
quantification. b, Scheme explaining the automated quantification strategy of images using CellProfiler software. 5 
First, the total intensity of the raw image, which is always the same size (4.5x104 µm2), was measured and then 6 
the area occupied by the protein was calculated by creating a mask. Then the normalized intensity was calculated 7 
by dividing the total intensity by the occupied area (DMP1, EMCN) or by the total cell density (FAM20C). When the 8 
total amount of a protein per region was analysed, we used the total intensity without further normalization to the 9 
area occupied by it (DMP1, pVEGFR2, MMP9). c, Dmp1, Osx and Runx2 RNAScope staining in the OF of a 5-10 
week-old femur. Scale bar 20 µm. d,e, Quantification of (d) Osx+ and (e) Runx2+ cells among Dmp1-expressing 11 
cells based on RNAScope images. n=3 per age. Pooled data from 2 independent experiments. Mean ± SD. f, 12 
Dmp1 and Osx RNAScope overview images from central and peripheral parts of the metaphysis at 5 and 5.5 weeks 13 
demonstrating the absence of Dmp1 expression in the GP. g, Quantification of the mean Dmp1 intensity per cell 14 
among Dmp1-expressing cells showing the peak at 4 weeks. n=3 per age, 4x105 µm2 area was always analysed 15 
per sample. Pooled data from 2 independent experiments. Mean ± SEM. 16 
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 1 
Extended Data Fig. 3: Identification of bulges and loss of type H vessels starting from 5.5-6 weeks of age 2 
in the centre of the ossification front. a, EMCN and MMP9 immunostaining with a separated nuclei channel 3 
(Hoechst, left panel), which was used to define the border (dashed line) between OF and GP, based on cell density. 4 
This border then was copied to the respective full-colour image (right panel) to identify the bulges in the GP in an 5 
unbiased way. Scale bar 50 µm. b, Quantification of EMCN intensity in the centre and periphery of the OF at 6 
different ages with a depiction of individual values per mouse in pairs. EMCN brightness decreases with ageing. 7 
At 4 and 5 weeks n=7, 5.5-6 weeks n=12, 8 weeks n=6, 12-15 weeks n=6. Pooled data from 6 independent 8 




Extended Data Fig. 4: Generation of Dmp1-deficient and Dmp1-floxed mice. a, Scheme showing the wild-type 2 
(top) and knockout version (bottom) of the Dmp1 gene. Exon 6, encoding 80% of the protein, was cut out using 3 
Crispr/Cas9 technology. The cutting was done 500bp upstream of Exon 6 and 500bp downstream of the open 4 
reading frame (ORF), and the whole intermediate region was removed. b, PCR bands of the Dmp1 gene in Dmp1-5 
/-, Dmp1+/- and Dmp1+/+ mice, where the band at ≈3800bp indicates the WT allele and at ≈1100bp the Dmp1-6 
 21 
deficient variant. Note that the wild-type band in Dmp1+/- mice is very faint because of the PCR competition with 1 
the significantly smaller knockout allele. c,d, Body weight (c) and femur length (d) of Dmp1-/-, Dmp1+/- and Dmp1+/+ 2 
mice at the age of 4.5-5 weeks. P values indicate the significance between Dmp1-/- versus Dmp1+/- and Dmp1+/+ 3 
mice. Two-tailed t-test. e, Representative photo of Dmp1-/- and Dmp1+/+ mice at the age of 15 weeks. f, 4 
Representative photo of Dmp1-/- and Dmp1+/+ femurs at the age of 5 months. g, Scheme showing the wild-type 5 
(top) and floxed version of the Dmp1 gene. LoxP sites were introduced 500bp upstream of Exon 6 and 500bp 6 
downstream of the ORF in the UTR region using Crisp/Cas9 technology. h, PCR bands of the Dmp1 gene in 7 
Dmp1fl/fl, Dmp1WT/fl and Dmp1WT/WT mice showing that the introduced loxP sites make the allele 34bp longer than 8 
the WT version. i, PCR showing the appearance of the genomic Dmp1-knockout band only in cells from Dmp1fl/fl 9 
mice that were transduced with a Cre-recombinase encoding retrovirus.  10 
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 1 
Extended Data Fig. 5: DMP1-deficient mice exhibit very high EMCN and MMP9 intensity and the growth 2 
plate is expanded and disorganised with enlarged SOX9 and RUNX2 zones. a, RUNX2 and SOX9 3 
immunostaining of metaphysis from 4.5-week-old Dmp1-/- and Dmp1+/+ mice. Scale bar 250 µm. b, OSX and EMCN 4 
immunostaining of femurs from 4.5-week-old Dmp1-/-, Dmp1+/- and Dmp1+/+ mice from one litter. Scale bar 100 µm. 5 
c,d, EMCN and MMP9 immunostaining of 4-week-old (c) and 20-week-old (d) femurs of Dmp1-/- and Dmp1+/- mice 6 
from one litter. Scale bar 100 µm (c) and 200 µm (d).  7 
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 1 
Extended Data Fig. 6: Osteoblast-specific Dmp1 deletion preserves type H vessel identity and impairs bone 2 
mineralization. a, Representative Dmp1 RNAScope images of control and Dmp1i∆OB OF. Scale bar 50 µm. b, 3 
Quantification of Dmp1 mRNA based on RNAScope images of control and Dmp1i∆OB mice at 6 weeks. 3 samples 4 
per group were randomly selected, out of 14 and 13, respectively, for control and Dmp1i∆OB groups, to determine 5 
the deletion efficiency. Two-tailed unpaired t-test. Mean ± SD. c, DMP1 immunostaining of OF in 6-week-old control 6 
and Dmp1i∆OB femurs. Scale bar 50 µm. d, Body weight of control and Dmp1i∆OB mice at 6 weeks (P42). e, EMCN 7 
and MMP9 immunostaining of 6-week-old control and Dmp1i∆OB femurs. Scale bar 250 µm. f, Femur length of 8 
control and Dmp1i∆OB mice at 6 weeks (P42). d,f, Pooled data from 3 independent experiments. Control n=14, 9 
Dmp1i∆OB n=13. Two-tailed unpaired t-test. Mean ± SD. g, Overview of von Kossa staining of undecalcified control 10 
and Dmp1i∆OB femur sections. Yellow dashed rectangles indicate the regions shown in Extended Data Fig. 6h and 11 
6i, and quantified in Extended Data Fig. 6j and 6k, respectively. Scale bar 200 µm. h, Von Kossa staining of 12 
undecalcified control and Dmp1i∆OB femur sections (ossification front). Scale bar 200 µm. i, Von Kossa staining of 13 
undecalcified control and Dmp1i∆OB femur sections (subchondral bone – articular cartilage area). Scale bar 50 µm. 14 
j,k, Quantification of mineralization rate in the ossification front (j) and subchondral bone (k) by measuring the von 15 
Kossa staining intensity in control and Dmp1i∆OB femurs. Age = 6 weeks. Control n=3, Dmp1i∆OB n=3. Two-tailed 16 
unpaired t-test. Median ± range.   17 
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 1 
Extended Data Fig. 7: DMP1 abundance negatively correlates with the activation of VEGFR2 in the 2 
ossification front and DMP1 treatment inhibits VEGF signalling in endothelial cells in vitro. a, DMP1 and 3 
phosphorylated VEGFR2 (pVEGFR2) immunostaining of the OF throughout postnatal development. Scale bar 50 4 
µm. b, pVEGFR2 immunostaining of bEnd.3 cells, which were either treated with VEGF only (left) or pre-treated 5 
with DMP1 (40 nM) for 3 hours before adding VEGF (50 ng/ml). Scale bar 25 µm. c, Quantification of the pVEGFR2 6 
intensity per cell of bEnd.3 cells, which were either treated with VEGF only or pre-treated with DMP1 before adding 7 
VEGF. Two-tailed Mann Whitney test. Mean. d, qPCR of cfos expression, one of the target genes of VEGF 8 
signalling, in bEnd.3 cells, which were treated either with DMP1 only, or with VEGF only, or first with DMP1 and 9 






Extended Data Fig. 8. Enhanced production of the DMP1-phosphorylating kinase FAM20C depends on 3 
mechanical forces sensed via PIEZO1 mechanoreceptor. a, Quantification of the FAM20C amount in the centre 4 
relative to the periphery in the OF of femurs from 6-week-old control and Dmp1i∆OB mice. Top P value indicates the 5 
insignificance between control and Dmp1i∆OB groups. Bottom P values show the significance between the intensity 6 
in the centre versus periphery upon paired analysis for every mouse. Two-tailed paired t-test within a group. Two-7 
tailed unpaired t-test between the groups. b, Quantification of the total FAM20C amount in the centre of the OF in 8 
the control and Dmp1i∆OB group. Two-tailed unpaired t-test. a,b, Pooled data from 3 independent experiments. 9 
Control n=12, Dmp1i∆OB n=13. Mean ± SD. c,d, Quantification of the intensities of FAM20C (c) and DMP1 (d) in 10 
control and loaded (centrifuged) femur slice samples. Pooled data from 2 independent experiments. n=5-6 (in one 11 
biological replicate staining for FAM20C was technically not possible due to the limited amount of material). Two-12 
tailed paired t-test. e,f, Quantification of FAM20C (e) and DMP1 (f) intensities in loaded control (left) and unloaded 13 
(operated, right) femurs after double neurectomy. Pooled data from 2 independent experiments. n=16. Two-tailed 14 
Wilcoxon matched-pairs signed rank test. g, Normalized number of reads mapping to the genes of 15 
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mechanoreceptors expressed by endothelial cells together with surrounding cells in the juvenile and adult OF. Data 1 
are derived from the transcriptome analysis shown in Fig. 1 and Extended Data Fig. 1. h, Representative Fam20c 2 
RNAScope images of control and Piezo1∆Dmp1 OF. Scale bar 50 µm. i, OSX immunostaining of control and 3 
Piezo1∆Dmp1 OF at 4 and 7 weeks of age. Scale bar 50 µm. j,k, Quantification of OSX intensity in the OF of control 4 
and Piezo1∆Dmp1 OF at 4 weeks (j) and 7 weeks (k) of age. Two-tailed unpaired t-test. Mean ± SD. l, FAM20C and 5 
DMP1 immunostaining of 4-week-old control and Piezo1∆Dmp1 ossification fronts. Scale bar 50 µm. m,n, 6 
Quantification of FAM20C (m) and DMP1 (m) intensities in 4-week-old control and Piezo1∆Dmp1 ossification fronts. 7 
Two-tailed unpaired t-test. Mean ± SD. o, Schematic depiction of loading distribution (red arrows) in the growth 8 





Extended Data Fig. 9: Graphical abstract of the study.3 
 28 
Materials and Methods 1 
Mice 2 
Tie2-GFP reporter mice (Tg(TIE2GFP)287Sato/J, Stock No: 003658) were purchased from Jackson 3 
Laboratory. For analysis of wild-type femurs, C57BL/6N and C57BL/6J mice were used. C57BL/6J 4 
mice were used for double neurectomy experiments. Dmp1-/- and Dmp1fl/fl mice were produced by 5 
microinjection of C57BL/6J zygotes with Cas9 protein and synthetic guide RNA gDMP#1 6 
(TTGGGAAGATAACCGCTTAG) and gDMP#2 (CAGCTGAGGCGAGTACCACA). Thereby Exon 7 
6, which encodes 80% of the DMP1 protein, was deleted to generate constitutive Dmp1-deficient mice 8 
(Extended Data Fig. 4). For inducible deletion of Dmp1, loxP sites were inserted at the site of the gRNA 9 
target sites flanking Exon 6 using a customized gene targeting vector: 500 bp upstream of Exon 6 and 10 
500 bp downstream of the open reading frame (ORF). Dmp1-floxed mice were bred with Col1a2-11 
CreERT2 mice, which were kindly provided by Prof. Dr. Thomas Blankenstein (Charité, Berlin). To 12 
induce Cre activity and gene deletion, 4-week-old offspring was injected intraperitoneally with 50 13 
mg/kg of tamoxifen (Sigma, T5648) for 5 consecutive days: P28-32. The resulting Dmp1i∆OB 14 
(CreERT2+/-Dmp1fl/fl) mutants and control (CreERT2-/-Dmp1fl/fl) mice were sacrificed on day P42 (6 15 
weeks) and the bones were collected for analysis. Piezo1fl/fl-Dmp1Cre and Piezo2fl/fl-Dmp1Cre were 16 
described before28. Cre-negative littermates were always used as controls. 17 
In all experiments, both genders were analysed together and no gender-specific differences were 18 
observed. All mice were bred under specific pathogen-free (SPF) conditions and treated according to 19 
the requirements of the German legislation. Mice were kept in approved animal-care facilities and were 20 
housed 4-5 per cage in standard individually ventilated cages, maintained with a 12h light/dark cycle at 21 
an ambient temperature of 21°C. All animal experiments were performed according to relevant laws 22 
and institutional guidelines and were approved by local animal ethics committees (LAGeSo license 23 
number G0175/19).  24 
Laser microdissection  25 
Tie2-GFP mice were sacrificed via cervical dislocation at 4 weeks or 12 weeks of postnatal 26 
development. Femurs were immediately collected and frozen in SCEM medium using dry ice-27 
 29 
isopropanol-hexane cooling bath. After freezing the blocks were kept at -80°C until cryosectioning. 1 
The temperature of the cryostat chamber and the knife was -32°C and -34°C, respectively. For 2 
cryosectioning, type D knife for hard tissue was used. All surfaces including the knife were cleaned 3 
with RNaseZap before use. Cryosectioning was performed with Kawamoto’s films for LMD. To 4 
minimize RNA degradation, 12 µm sections were mounted into the metal frame directly after cutting 5 
and transported in the evaporating phase of liquid nitrogen. Laser microdissection was performed using 6 
Leica LMD7 device with fluorescent lamp for endothelial cell identification. To minimize the humidity 7 
during microdissection, constant flow of evaporating liquid nitrogen was applied. The microdissected 8 
pieces were collected into lysis buffer (ARCTURUS® PicoPure® RNA Isolation Kit). Approximately 9 
50 pieces were collected from each sample. Immediately after collection, the Eppendorf tube containing 10 
the sample was briefly centrifuged and incubated at 42°C for 10 min. Afterwards, it was vortex shortly 11 
and frozen on dry ice and kept at -80°C until RNA isolation.  12 
RNA sequencing and analysis 13 
RNA was isolated using ARCTURUS® PicoPure® RNA Isolation Kit according to manufacturer's 14 
instructions. Illumina libraries were generated using SMART-Seq v4 Ultra Low Input RNA Kit (Takara 15 
Clontech) and Nextera XT DNA Sample Preparation Kit (Illumina), with up to 10 ng of purified cDNA. 16 
The quality of synthesized cDNA was checked using Bioanalyzer (Agilent). For sequencing, Illumina 17 
NextSeq500 device was used generating 75 bp paired-end reads. Reads were mapped to the mouse 18 
mm10 genome using TopHat2 (PMID: 23618408) and Bowtie2 (PMID: 22388286) with default 19 
settings46. Further analysis was done with R 3.4.0 using the default settings of the deseq2 package 20 
(PMID:25516281). To identify the genes with the highest significance, fold change and decent 21 
expression level, the following filtering strategy was applied: mean expression value >500, Log2 FC > 22 
0.66, P < 10-5. The heat map for selected genes was generated by plotting log2-transformed read counts.  23 
Immunohistochemistry 24 
Mouse bones were processed as described previously47. Briefly, the bones were collected, cleaned from 25 
surrounding tissue and muscles, and immediately fixed in 4% freshly prepared ice-cold 26 
paraformaldehyde (PFA) for 4 h on ice. Afterwards, the bones were washed 3 times in ice-cold PBS 27 
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followed by decalcification in 0.5M EDTA solution (pH=7.5) for 24 h under constant agitation at 4°C. 1 
Cryoprotection was done overnight in 20% sucrose and 2% PVP solution at 4°C immediately after 2 
decalcification. Afterwards, 5 ml of embedding medium (8% gelatine, 20% sucrose and 2% PVP in 3 
PBS) was added per falcon tube and the bones were incubated in it for 45 min at 60°C followed by 4 
embedding into cryomolds. The femurs were always oriented the same way with the anterior side facing 5 
the bottom of the mould. After embedding the samples were left at room temperature (RT) for 30 min 6 
for complete medium solidification. The blocks were kept at -80°C in air-tight containers until 7 
cryosectioning. Cryosectioning was performed using NX70 ThermoFischer cryostat at -25°C and -27°C 8 
for chamber and blade, respectively. The disposable low-profile blades N35 for hard tissue (207500006, 9 
Feather) were used for cutting. 100 µm sections were generated and transferred onto Superfrost slides 10 
(J1800AMNT, Thermo Fisher Scientific). The slides were kept at -20°C until staining. For 11 
immunostaining, bone sections were air-dried, permeabilized in 0.3% Triton X-100 for 15 min, blocked 12 
in 10% donkey serum at RT for 30 min, and incubated with the primary antibodies diluted in 5% donkey 13 
serum in PBS for 2 h at RT or overnight at 4°C. After primary antibody incubation, sections were 14 
washed with PBS three times and incubated with corresponding secondary antibodies for 1 h at RT. 15 
Nuclei were counterstained with Hoechst (1:1000, 33342, Thermo Fischer Scientific). After incubation 16 
with secondary antibodies, sections were washed three times with PBS and mounted with Fluoromount-17 
G medium (00-4958-02, Thermo Fischer Scientific).  18 
RNAScope  19 
Freshly dissected mouse femurs were fixed in 4% freshly prepared PFA for 24 h at 4°C followed by 20 
washings in PBS. Cryoprotection was performed via overnight incubations in 10, 20 and 30% sucrose 21 
at 4°C. Bones were frozen in SCEM medium. The frozen blocks were kept at -80°C until 22 
cryosectioning. Kawamoto cryofilms type 3C(16UF) were used for cryosectioning. The sections were 23 
air-dried in the cryotome for 15 min and stored at -80°C in the slide box with molecular sieves inside. 24 
For RNAScope assay, sections were air-dried at RT for 5 min, washed in PBS for 5 min and baked on 25 
60°C hot plate for 30 min followed by additional fixation in 4% PFA at 4°C for 15 min. Afterwards, 26 
the sections underwent 5 min dehydration steps in ethanol gradient: 50, 70 and 100% (x2). The sections 27 
were air-dried again for 5 min followed by 10 min incubation in hydrogen peroxide and washings in 28 
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distilled water. The target retrieval buffer was prewarmed in the steamer for ~10 min up to 75°C. The 1 
slides were submerged into it and left in the steamer for 10 min. The temperature in the steamer was 2 
95°C. Afterwards, the slides were washed in distilled water and dehydrated in 100% ethanol for 10-15 3 
sec. The slides were air-dried for 5 min at RT or overnight. Protease III was applied, and the slides were 4 
incubated in the Hybez Oven for 30 min followed by washings in distilled water. The rest of the 5 
RNAScope procedure was performed according to the standard RNAScope® Multiplex Fluorescent v2 6 
Assay protocol. 7 
Double neurectomy 8 
Mice received pre-emptive pre-operative subcutaneous analgesia. 5 mm pieces of sciatic and femoral 9 
nerves of the right hind limb were cut out in 4-4.5-week-old C57BL/6J mice under general anaesthesia 10 
using isoflurane. After surgery, the mice were housed without tubes and on soft bedding. It was 11 
observed that all mice dragged the operated right limb without stepping on it. Mice were sacrificed at 12 
the age of 5.5-6 weeks and the bones were collected for further analysis. The contralateral left femur 13 
was always used as control and was analysed in pair with the operated unloaded right femur. 14 
In vitro culture of bone slices 15 
Femurs were collected from 4-week-old C57BL/6J mice. Half of the bone together with knee 16 
metaphysis was cut and frozen in 2.5% agarose on ice with subsequent cooling in liquid nitrogen. Under 17 
the sterile work bench, the frozen block was fixed on the sample holder for cryosectioning, which was 18 
placed on dry ice. 400-500 µm-thick slices of femur were produced using sterile disposable blade for 19 
hard tissue. Every slice was placed into a well of a 96-well PRC plate filled with StemMACS™ 20 
OsteoDiff Media (Miltenyi Biotec). The position of the slice is depicted in Fig. 4a. At least two slices 21 
per femur were generated, each of them was placed into a separate plate. The plates were kept at 37°C 22 
with 5% CO2 in a humidified atmosphere. One plate with slices was centrifuged twice daily at 19g (the 23 
lowest possible speed of the centrifuge) at 37°C for 30 min. The control plate was not subjected to 24 
centrifugation. The medium was changed every 2.5 days. After 5 days of culture, the slices were fixed 25 
in 4% PFA on ice for 30 min followed by washings in PBS and decalcification for 30 min in 0.5M 26 
EDTA on the cooling element under constant agitation. Cryoprotection was done in 20% sucrose and 27 
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2% PVP solution in PBS at 4°C overnight. The slices were frozen in embedding medium (8% gelatine, 1 
20% sucrose and 2% PVP in PBS). 100 µm sections were prepared using the NX70 Cryotome (Thermo 2 
Fischer Scientific). The sections were stored at -20°C until immunostaining. The staining was 3 
performed as described in the paragraph “Immunohistochemistry”. Paired analysis was done based on 4 
the slices derived from the same mouse. 5 
Image acquisition and analysis 6 
All immunofluorescent and RNAScope-multifluorescent stainings were acquired at high resolution 7 
with Zeiss LSM-880 confocal microscope using 20x or 63x objectives. All microscope settings 8 
including laser power were kept constant throughout the experiments within the same type of samples 9 
and same staining panels. All immunostained samples were always acquired in Z-stack mode followed 10 
by maximum intensity projection. The images were processed and analysed using ImageJ and 11 
CellProfiler software, in compliance with Nature’s guide for digital images. 12 
For quantification of immunofluorescent images, a region of 300µm width and 150µm depth (from the 13 
growth plate towards the caudal region) was always analysed. For RNAScope-multifluorescent images, 14 
the central and peripheral regions of 600µm x 300µm area underneath the growth plate were analysed. 15 
A cell was counted as Runx2+ or Osx+ if it contained at least one bright dot of the corresponding probe 16 
at 200x magnification.  17 
Endothelial cell culture  18 
The mouse capillary endothelial cell line bEnd.348 was kindly provided by Prof. Dr. Alf Hamann 19 
(Charité, Berlin). The cells were cultured in ATCC-formulated Dulbecco's Modified Eagle's Medium 20 
(Catalogue No. 30-2002) containing 10% FCS and 100 U/mL penicillin and 100 mg/mL streptomycin. 21 
The cells were maintained at 37°C with 5% CO2 in a humidified atmosphere. Cells were cultured with 22 
recombinant DMP1 (40 nM) for 4 or 24 h. At the end of this incubation time, VEGF (50ng/ml) was 23 
added to the cells for 15-20 min with subsequent cell fixation for immunocytochemistry or RNA 24 
collection for qPCR. 25 
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Immunocytochemistry  1 
bEnd.3 cells were cultured in 8- or 16-well slide chambers (Tissue Tek). By the end of the experiment, 2 
cells were fixed in 4% freshly prepared ice-cold PFA for 10 min. Afterwards, they were washed 3 times 3 
with PBS and blocked in PBS containing 10% FCS for 30 min. The primary antibodies were applied 4 
for 1 h at RT in PBS containing 5% FCS and 0.1% Tween-20. After primary antibody incubation, cells 5 
were washed 3 times with PBS-Tween-20 (0.1%) and incubated with appropriate secondary antibodies 6 
diluted in PBS containing Hoechst (1:1000) for 1 h at RT. Finally, the cells were washed again 3 times 7 
with PBS and mounted using Fluoromount-G medium (Thermo Fischer Scientific).  8 
qPCR 9 
mRNA of bEnd.3 cells was isolated with the NucleoSpin RNA XS kit (Macherey Nagel) according to 10 
the manufacturer’s protocol. cDNA was generated with TaqMan Reverse Transcription Reagents and 11 
quantified with PowerUp™ SYBR™ Green Master Mix using QuantStudio Real-Time PCR System 12 
(Thermo Fischer Scientific). The following primers were used: Fos (forward: 13 
CACTCCAAGCGGAGACAGAT, reverse: TCGGTGGGCTGCCAAAATAA), Gapdh (forward: 14 
AAGGTGATCCCAGAGCTGAA, reverse: CTGCTTCACCACCTTCTTGA). Fos expression was 15 
normalized to Gapdh.  16 
Von Kossa staining 17 
The samples were prepared as described in paragraph “RNAScope”. The staining was done according 18 
to the manufacturer’s instructions (Silver plating kit acc. to von Kossa, Merck Millipore, #100362). 19 
Briefly, 10 µm undecalcified femur sections were placed in distilled water for 1 min followed by 20 
incubation in silver nitrate solution for 5 min under direct sunlight. Afterwards, the samples were 21 
washed in running tap water for 3 min and incubated in sodium thiosulfate solution for 5 min. Then the 22 
samples were washed in running tap water for 1 min and mounted in water-based mounting medium. 23 
The images were acquired with Leica DM750 equipped with Leica ICC50 W Camera Module using 24 
LAS software and analysed with ImageJ software (version 2.0.0). 25 
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Statistics  1 
Statistical analysis was carried out using GraphPad Prism software (version 8.2). Normal distribution 2 
was tested using Shapiro-Wilk and Kolmogorov-Smirnov tests. In case of normal distribution 3 
parametric two-tailed paired t-test or unpaired t-test were used. For non-Gaussian distribution, non-4 
parametric tests were used: two-tailed Wilcoxon test for paired analysis and two-tailed Mann-Whitney 5 
test for unpaired analysis. P < 0.05 was considered significant. Mice with body weight that was >20% 6 
below the average weight of their littermates were excluded from the inducible Dmp1-deletion 7 
experiments. All image quantifications were done automatically upon manual blinded selection of 8 
central and peripheral OF regions of the same size.  9 
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MMP-9, biotin 1:200 BAF909 Novus 
Integrin β3 1:100 4702S Cell Signalling 
FAM20C 1:100 25395-1-AP Proteintech 








MCM-BP 1:100 ab122478 Abcam 
PDGF R beta Biotinylated 1:100 BAF1042 R&D systems 
Phospho-VEGF Receptor 2 
(Tyr1175) (19A10) 
1:100 
2478S Cell Signaling 
VEGFR2/KDR/Flk-1 1:50 AF644 R&D systems 





Name Dilution Catalogue 
number 
Company 
Donkey anti-Rabbit IgG (H+L) 






Goat anti-Rabbit IgG (H+L) 





Donkey anti-Rabbit IgG (H+L) 






Donkey anti-Rabbit IgG (H+L) 
Cross-Adsorbed Secondary 

















Donkey anti-Rat IgG (H+L) Cross 
Adsorbed Secondary Antibody, 






Donkey anti-Rat IgG (H+L) Cross 
Adsorbed Secondary Antibody, 






Donkey anti-Rat IgG (H+L) Cross-







Donkey anti-Goat IgG (H+L) Alexa 
Fluor 633 
1:500 A-21082 Thermo Fisher 
Scientific 





Name Catalogue number Company 
Embedding medium SCEM C-EM001 Section-Lab 
2 propanol ≥99,5 %, Ph.Eur., reinst.  CP41.3 Carl Roth 
n-Hexane 7339.1 Carl Roth 
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Thermo Fisher Scientific 
 
ARCTURUS® PicoPure® RNA Isolation 
Kit 
KIT0204 Thermo Fisher Scientific 










20% Paraformaldehyde (formaldehyde) 
aqueous solution 
50-980-492 Science Services 





Polyvinylpyrrolidon K 90 CP15.1 Carl Roth 
Gelatine 4274.3 Carl Roth 
D(+)-Saccharose 4621.1 Carl Roth 
Tissue Freezing Medium 14020108926 Leica biosystems 
Triton x-100 93418 Fluka BioChemika 
Tween-20 P1379 Sigma-Aldrich 
Fluoromount-G mounting medium 00-4958-02 Thermo Fisher Scientific 
ATCC-formulated Dulbecco's Modified 
Eagle's Medium 
30-2002 ATCC 
StemMACS™ OsteoDiff Media 130-091-67 Miltenyi Biotec 
Tamoxifen T5648-1G Sigma-Aldrich 
Recombinant mouse VEGF-A 493-MV-005 R&D systems 
Recombinant mouse DMP1 4386-DM-050 R&D systems 
Power SYBR Green Master Mix 4368708 Thermo Fisher Scientific 
Taq Man cDNA polymerase 4304134 R&D systems 
Hoechst 33342 Solution (20 mM) 62249 Thermo Fisher Scientific 
Opal 570 FP1488001KT Akoya Biosciences 
Opal 620 FP1495001KT Akoya Biosciences 
Opal 650 FP1496001KT Akoya Biosciences 







Cryomoulds SA62534-15 Tissue-Tek 
Kawamoto’s LMD tape C-FL001 Section-lab 
Kawamoto’s tape 3C(16UF) C-FUF304 Section-lab 
Thin-walled, frosted lid, RNase-free PCR 
tubes (0.2 mL) 
AM12225 
 
Thermo Fischer Scientific 
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Microtome Blade - N35 for hard tissue 207500006 Feather 
Superfrost Plus slides J1800AMNT Thermo Fischer Scientific 
Polysine slides 10219280 Thermo Fischer Scientific 
Molecular sieves  8483 Carl Roth 
Microtube tough-spots N120.1 Carl Roth 
Coverslips LH24.1 Carl Roth 
16-well Chamber Slide with removable 
wells 
178599 Thermo Fischer Scientific 
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